Development of a combination cancer therapy utilizing oncolytic adenovirus with chemotherapy
| Project/Area Number |
15K20381
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
Matsuda Aya 北海道大学, 歯学研究院, 特別研究員(RPD) (60514312)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 腫瘍溶解ウイルス / 口腔がん / 抗がん剤 / 抗癌剤 |
|---|
| Outline of Final Research Achievements |
Oncolytic adenovirus is an attractive tool for cancer therapy. We developed a novel oncolytic adenovirus ( AdΔE4) based on the ARE-mRNA stabilization system. In this study, we examined the combination effect of AdΔE4 with cisplatin (CDDP). In the case of combined use of AdΔE4 with CDDP, the cell survival rate of CDDP resistant cancer cells were very lower compared with those of single treatments. These results indicate that new virus available for the combination cancer therapy with CDDP. To evaluate the mechanism of the combination effect of AdΔE4 with CDDP, we treated cancer cells by CDDP. CDDP treatment of cancer cells resulted in higher expression of HuR protein in the cytoplasm of cancer cells. These results suggest that the HuR mediated ARE-mRNA stabilization system plays an important role in AdΔE4 replication.
|
Report
(3 results)
Research Products
(16 results)
